Abstract: A device and a method for generating synchronous corpus is disclosed. Firstly, script data and a dysarthria voice signal having a dysarthria consonant signal are received and the position of the dysarthria consonant signal is detected, wherein the script data have text corresponding to the dysarthria voice signal. Then, normal phoneme data corresponding to the text are searched and the text is converted into a normal voice signal based on the normal phoneme data corresponding to the text. The dysarthria consonant signal is replaced with the normal consonant signal based on the positions of the normal consonant signal and the dysarthria consonant signal, thereby synchronously converting the dysarthria voice signal into a synthesized voice signal. The synthesized voice signal and the dysarthria voice signal are provided to train a voice conversion model, retain the timbre of the dysarthria voices and improve the communication situations.

Abstract: A device and a method for generating synchronous corpus is disclosed. Firstly, script data and a dysarthria voice signal having a dysarthria consonant signal are received and the position of the dysarthria consonant signal is detected, wherein the script data have text corresponding to the dysarthria voice signal. Then, normal phoneme data corresponding to the text are searched and the text is converted into a normal voice signal based on the normal phoneme data corresponding to the text. The dysarthria consonant signal is replaced with the normal consonant signal based on the positions of the normal consonant signal and the dysarthria consonant signal, thereby synchronously converting the dysarthria voice signal into a synthesized voice signal. The synthesized voice signal and the dysarthria voice signal are provided to train a voice conversion model, retain the timbre of the dysarthria voices and improve the communication situations.

Abstract: Provided is a method of treating cancer with a tyrosine-kinase inhibitor. In particular, provided is a method of treating cancer containing a mutated epidermal growth factor receptor (EGFR) with compound A, or a pharmaceutically acceptable salt thereof, preferably a maleate or dimaleate salt of compound A.

Abstract: The present invention relates to methods useful for treating and/or preventing mucositis using an active vitamin D compound.

Abstract: This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.

Abstract: The present invention relates to methods useful for treating and/or preventing mucositis using an active vitamin D compound.

Abstract: There are disclosed methods for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing regimen and/or schedules based on the patient's MGMT level. Additional improved methods for treating patients with temozolomide are also disclosed.

Abstract: The invention relates to a rake receiver and a method for de-spreading thereof. A plurality of noise branches is adopted for producing a plurality of noise components in the rake receiver. Next, a noise combining unit adjusts each noise component according to a plurality of noise weights, so as to combine the noise components to obtain an interference-plus-noise estimation value. The rake receiver eliminates the noises in the main signal generated by the signal branches through using the interference-plus-noise estimation value. Therefore, the performance of a receiving terminal can be enhanced.

Abstract: The present invention relates to methods useful for treating and/or preventing radiation- and/or chemical-induced toxicity in non-malignant tissue using a protease activated receptor-1 (PAR-1) inhibitor. In particular, use of a protease activated receptor-1 (PAR-1) inhibitor to treat and/or prevent acute and chronic adverse effects of radiation and/or chemical exposure (e.g., to one or more of the following: intestine, lung, oral mucosa, or other organs).

Abstract: The present invention provides combination compositions comprising Pt based compounds, including satraplatin, along with another chemotherapeutic agent such as temozolomide or lonafarnib. The combinations are useful for the prevention or treatment of cancer.

Abstract: There are disclosed methods for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing regimen and/or schedules based on the patient's MGMT level. Additional improved methods for treating patients with temozolomide are also disclosed.